Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ICMT | O60725 | 17/20 | 0.64 |
| ▸ | CDC25A | P30304 | 1/20 | 0.50 |
| ▸ | MCL1 | Q07820 | 2/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5256680 | 0.80 | ICMT (0.61) | ICMTCDC25AMCL1 | |
| SCHEMBL3667313 | 0.79 | ICMT (0.97) | ICMTCDC25A | |
| SCHEMBL4988587 | 0.79 | ICMT (0.74) | ICMTCDC25AMCL1 | |
| SCHEMBL11893393 | 0.78 | ICMT (1.00) | ICMTCDC25A | |
| SCHEMBL10965765 | 0.77 | ICMT (0.71) | ICMTCDC25AMCL1 | |
| SCHEMBL12475231 | 0.77 | CDC25A (0.42) | ICMTCDC25A | |
| SCHEMBL14522478 | 0.77 | ICMT (0.58) | ICMTCDC25AMCL1 | |
| SCHEMBL8086295 | 0.77 | ICMT (0.71) | ICMTCDC25A | |
| SCHEMBL8088107 | 0.76 | ICMT (0.70) | ICMTCDC25AMCL1 | |
| SCHEMBL5253839 | 0.76 | ICMT (0.69) | ICMTCDC25AMCL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070088019-A1 | Macroheterocyclic compounds as kinase inhibitors | JANSSEN PHARMACEUTICA, N.V. (BE) | 2007-04-19 | — | — | US | disclosed |
| WO-2007041195-A2 | MACROHETEROCYLIC COMPOUNDS AS KINASE INHIBITORS | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-04-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070088019-A1 | Macroheterocyclic compounds as kinase inhibitors | MAP3K2, MAP3K20, MAP3K13 | ICMT 4479/4885CDC25A 557/4885MCL1 371/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.